

## Optimizing IgAN Management – Additional Resources

### **Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial**

Heerspink HJL, Radhakrishnan J, et al. PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. PMID: 37015244.

Link: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(23\)00569-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext)

### **KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases**

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021. PMID: 34556256.

Link: [https://www.kidney-international.org/article/S0085-2538\(21\)00562-7/fulltext](https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext)

### **Evaluating a New International Risk-Prediction Tool in IgA Nephropathy**

Barbour SJ, Coppo R, et al. International IgA Nephropathy Network. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. *JAMA Intern Med*. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600. Erratum in: *JAMA Intern Med*. 2019 Jul 1;179(7):1007. PMID: 30980653; PMCID: PMC6583088.

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583088/>

### **Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group**

Trimarchi H, Barratt J, et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int*. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22. PMID: 28341274.

Link: [https://www.kidney-international.org/article/S0085-2538\(17\)30101-1/fulltext](https://www.kidney-international.org/article/S0085-2538(17)30101-1/fulltext)

## **Sparsentan: First Approval**

Syed YY. Sparsentan: First Approval. *Drugs*. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x. PMID: 37022667.

Link: <https://link.springer.com/article/10.1007/s40265-023-01864-x>

## **Long-term outcomes in IgA nephropathy**

Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Long-Term Outcomes in IgA Nephropathy. *Clin J Am Soc Nephrol*. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.000000000000135. Epub 2023 Apr 13. PMID: 37055195.

Link: [https://journals.lww.com/cjasn/Fulltext/2023/06000/Long\\_Term\\_Outcomes\\_in\\_IgA\\_Nephropathy.9.aspx](https://journals.lww.com/cjasn/Fulltext/2023/06000/Long_Term_Outcomes_in_IgA_Nephropathy.9.aspx)

## **A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy**

Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. *N Engl J Med*. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. PMID: 37916620.

Link: <https://pubmed.ncbi.nlm.nih.gov/37916620/>

## **Targeting the Endothelin A Receptor in IgA Nephropathy**

Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, Haile-Meskale R, Rizk DV, King A. Targeting the Endothelin A Receptor in IgA Nephropathy. *Kidney Int Rep*. 2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. PMID: 38025243; PMCID: PMC10658204.

Link: <https://pubmed.ncbi.nlm.nih.gov/38025243/>

## **Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial**

Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NeflgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial. *Lancet*. 2023 Sep 9;402(10405):859-870. doi:

10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Erratum in: Lancet. 2023 Sep 9;402(10405):850. PMID: 37591292.

<https://pubmed.ncbi.nlm.nih.gov/37591292/>